Editorial Comment on “Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease”
International Journal of Urology · 2023
DOI: 10.1111/iju.15246 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Urology, 2023. Verfasst von Shuya Kandori. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency, Chronic, Kidney Neoplasms. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
ORCID-Profile: Shuya Kandori
Zitieren
APA
Kandori, S. (2023). Editorial Comment on “Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease”. International Journal of Urology. https://doi.org/10.1111/iju.15246
Vancouver
Kandori S. Editorial Comment on “Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease”. International Journal of Urology. 2023. doi:10.1111/iju.15246
BibTeX
@article{Kandori2023,
author = {Kandori, Shuya},
title = {Editorial Comment on “Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre‐dialysis chronic kidney disease or end‐stage renal disease”},
journal = {International Journal of Urology},
year = {2023},
doi = {10.1111/iju.15246}
}
EUVIMED